| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Hydrocodone bitartrate 7.5 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 5 mg and paracetamol 556 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 650 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 10 mg and paracetamol 660 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 7.5 milligram and paracetamol 750 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol 325 mg + oxycodonhydrochlorid 5 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol 500 mg + oxycodonhydrochlorid 5 mg kapselformet tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely oxycodone hydrochloride 5 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + pentazocinhydrochlorid kapselformet 650 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 50 mg and paracetamol 325 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Dextropropoxyphene napsylate 100 mg and paracetamol 650 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and carisoprodol 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely aspirin 325 milligram and oxycodone hydrochloride 2.25 milligram and oxycodone terephthalate 190 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and oxycodone hydrochloride 4.5 mg and oxycodone terephthalate 380 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + pentazocinhydrochlorid 325 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| brompheniraminmaleat 2 mg + guaifenesin 200 mg + hydrocodonhydrogentartrat 5 mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| brompheniraminmaleat 2 mg + hydrocodonhydrogentartrat 1,7 mg + pseudoephedrinhydrochlorid 30 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat 2 mg + hydrocodonbitartrat 2,5 mg + phenylephrinhydrochlorid 5 mg væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 10 mg + promethazinhydrochlorid 6,25 mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 10 mg + pseudoephedrinhydrochlorid 30 mg + triprolidinhydrochlorid 1,25 mg væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Homatropine methylbromide + hydrocodone bitartrate 1.5mg/5mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| homatropinmethylbromid 1,5 mg + hydrocodonbitartrat 5 mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Homatropine methylbromide 1.5 mg and hydrocodone bitartrate 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonhydrogentartrat 5 mg + kaliumguaiacolsulfonat 300 mg væske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely pethidine hydrochloride 50 milligram and promethazine hydrochloride 25 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid 50 mg + promethazinhydrochlorid 50 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + hydrocodonbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 10 milligram and paracetamol 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 30 mg/1 ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| opiumtinktur med kamfer 2 mg/5 ml flydende |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Belladonna alkaloid 16.2 mg and opium 30 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Belladonna alkaloid 16.2 mg and opium 60 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulphate 30mg/30mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Morphine sulphate 10mg/1mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 70micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 52.5micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 35micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxycodone hydrochloride 5mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxymorphonhydrochlorid 1 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxymorphonhydrochlorid 1,5 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing aspirin and carisoprodol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + pentazocinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely hydrocodone bitartrate 2.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + alkohol + codeinphosphat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + oxycodonhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + hydrocodonbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| paracetamol + propoxyphennapsylat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid + promethazinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat + promethazinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + oxycodonhydrochlorid + oxycodonterephthalat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| levorphanoltartrat 2 mg/ml injektionsvæske, opløsning, hætteglas a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| levorphanoltartrat 2 mg/ml injektionsvæske, opløsning, hætteglas a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing bromazine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morfinsulfat 10 mg/5 ml sukkerfri oral opløsning 5 ml enhedsdosis, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| brompheniraminmaleat + hydrocodonhydrogentartrat + pseudoephedrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonbitartrat + ibuprofen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| homatropinmethylbromid + hydrocodonbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| opium + belladonna |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| brompheniraminmaleat + codeinphosphat + phenylpropanolaminhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat + pseudoephedrinhydrochlorid + triprolidinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| levorphanoltartrat 2 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| naloxonhydrochlorid + pentazocinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| chlorpheniraminmaleat + hydrocodonbitartrat + phenylephrinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonhydrogentartrat + kaliumguaiacolsulfonat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + pentazocinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing cyclizine and dipipanone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing aspirin and papaveretum (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Memantine (substance) |
Is a |
True |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Noradrenaline reuptake inhibitor |
Is a |
True |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hallucinogen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| bivirkning af anæstesi og medicinske gasser |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| General anesthetic drug adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Intravenous anesthetics adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Etomidate adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Ketamine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Propofol adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Thiopentone adverse reaction (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Methohexitone adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Inhalational anesthetics adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Enflurane adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| bivirkning af anæstetisk ether |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Halothane adverse reaction (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Isoflurane adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Trichloroethylene adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Desflurane adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Local anesthetic drug adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Bupivacaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Cinchocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Prilocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Lignocaine adverse reaction (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Cocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Benzocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Amethocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Oxybuprocaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Procaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
FHIR